IDOV-Immune / ViroMissile - LARVOL DELTA

ViroMissile…announced the initiation of a first-in-human clinical trial evaluating IDOV-Immune, its investigational oncolytic vaccinia virus therapy, in patients with advanced solid tumors (NCT06910657) (GlobeNewswire) - "Additional trial sites across the United States are expected to begin enrolling in 2026, pending clearance of the U.S. IND. The first patient was dosed at The Alfred Hospital in Melbourne, Victoria, Australia."

Trial status • Solid Tumor